Gilead Sciences (GILD) Given a $80.00 Price Target at Credit Suisse Group

Gilead Sciences (NASDAQ:GILD) received a $80.00 price objective from research analysts at Credit Suisse Group in a note issued to investors on Wednesday. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective points to a potential downside of 2.75% from the stock’s previous close.

GILD has been the subject of a number of other reports. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday. Leerink Swann reduced their target price on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating for the company in a report on Wednesday. Mizuho boosted their target price on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. BMO Capital Markets reduced their target price on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Finally, BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Thursday, December 14th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $85.84.

Gilead Sciences (GILD) traded down $0.50 during trading hours on Wednesday, reaching $82.26. 2,482,841 shares of the company were exchanged, compared to its average volume of 9,602,549. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $89.54. The stock has a market capitalization of $107,830.00, a price-to-earnings ratio of 23.73, a PEG ratio of -1.77 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 48.88%. The firm’s revenue was down 18.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.70 earnings per share. sell-side analysts predict that Gilead Sciences will post 6.47 EPS for the current fiscal year.

In other Gilead Sciences news, Chairman John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total value of $4,178,000.00. Following the sale, the chairman now owns 3,046,766 shares in the company, valued at approximately $254,587,766.96. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 578,333 shares of company stock worth $44,100,508. 1.30% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Welch Investments LLC purchased a new position in shares of Gilead Sciences during the 3rd quarter valued at approximately $108,000. Wealthcare Advisory Partners LLC purchased a new position in shares of Gilead Sciences during the 3rd quarter valued at approximately $133,000. Horan Capital Advisors LLC. purchased a new position in shares of Gilead Sciences during the 3rd quarter valued at approximately $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Gilead Sciences during the 2nd quarter valued at approximately $147,000. Finally, Hanson & Doremus Investment Management lifted its position in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares in the last quarter. Institutional investors and hedge funds own 75.84% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/02/08/gilead-sciences-gild-given-a-80-00-price-target-at-credit-suisse-group.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit